In Brief: Biofield
This article was originally published in The Gray Sheet
Executive Summary
Biofield: Begins patient enrollment for a 1,000-patient, six-center U.S. clinical trial of the Biofield Breast Examination (BBE) system, a non-invasive device designed to detect breast cancer by measuring and analyzing electrical potentials in breast tissue. Results of a recent European study of the device involving 261 patients demonstrate that the device detected 97% of malignancy cases (128/132), with a specificity of 79%. The firm plans a European launch in early 1996; Biofield officials say they are currently developing strategic alliances for sales, marketing and distribution in Europe...